{"id":949643,"date":"2026-04-07T16:40:01","date_gmt":"2026-04-07T20:40:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\/"},"modified":"2026-04-07T16:40:01","modified_gmt":"2026-04-07T20:40:01","slug":"avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\/","title":{"rendered":"AVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li>\n          <em>Cohealyx<\/em>\u00ae<em> multi-center study interim analysis and new case data to be presented<\/em><\/li>\n<li>\n          <em>RECELL<\/em>\u00ae<em> and PermeaDerm<\/em>\u00ae<em> data reinforce a comprehensive approach to wound healing<\/em><\/li>\n<li>\n          <em>Evidence demonstrates potential to improve outcomes while reducing hospital length of stay and optimizing resource utilization<\/em><\/p>\n<\/li>\n<\/ul>\n<p>VALENCIA, Calif., April  07, 2026  (GLOBE NEWSWIRE) &#8212; AVITA Medical\u00ae, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced its presence at the 2026 American Burn Association (ABA) Annual Meeting, where new clinical study data on Cohealyx will be presented at a Company-sponsored symposium, alongside investigator-led presentations showcasing real-world clinical experience across the Company\u2019s wound care portfolio.<\/p>\n<p>&#8220;The data being presented at ABA reinforces the strong clinical foundation behind RECELL, while introducing new case-based insights on Cohealyx and early findings from our ongoing multi-center real world study,\u201d said Cary Vance, Interim Chief Executive Officer of AVITA Medical. \u201cTogether, this work reflects a more complete approach to wound healing, one that not only closes wounds, but helps patients return to their lives faster.\u201d<\/p>\n<p>Across 19 presentations and 3 Company-sponsored events, AVITA Medical and its clinical partners will highlight real-world experience with RECELL, Cohealyx, and PermeaDerm, underscoring a comprehensive approach to wound management designed to improve patient outcomes while reducing hospital length of stay and optimizing resource utilization.<\/p>\n<p>New data on Cohealyx, the Company\u2019s collagen-based dermal matrix designed to support readiness for skin-grafting, will include investigator-led case experience alongside an interim analysis from the Company\u2019s ongoing Cohealyx-I multi-center study. These findings, evaluating time to skin grafting as a key endpoint, will be featured at AVITA Medical\u2019s symposium.<\/p>\n<p>At the meeting, AVITA Medical will also debut its new booth experience, centered on the theme Healing at the Speed of Life\u2122, a vision for advancing burn and acute wound care beyond wound closure toward recovery outcomes that prioritize mobility, function, and quality of life.<\/p>\n<p>\n        <strong>Full list of investigator-led presentations:<\/strong>\n      <\/p>\n<table style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong>#<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong>Product<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong>Abstract Title<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong>Presenter*<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">1<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">RECELL<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Global Clinical Evidence Demonstrates Skin Cell Suspension Autograft as a Standard of Care for Wounds (541)<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Scott Hultman, MD, MBA, FACS, FABA<br \/>WakeMed Health and Hospitals, NC<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">2<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">RECELL<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Skin Cell Suspension Autograft Reduces Length of Stay by 36% in Deep Partial-Thickness Burns: Analysis of BCQP Registry Data (523)<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Jonathan Schoen, MD, MPH, FACS, FABA<br \/>University Medical Center New Orleans, LA<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">3<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">RECELL disease education<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Clinical and economic outcomes of autologous skin grafts: A retrospective claims database analysis (889)<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Roselle Crombie, MD, MPH, FABA<br \/>Connecticut Burn Center, CT<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">4<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Cohealyx disease education<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Establishing Clinical Benchmarks for Dermal Matrices in Full-thickness Wound Management: Analysis of Role in Complex Closure (963)<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Roselle Crombie, MD, MPH, FABA<br \/>Connecticut Burn Center, CT<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">5<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">RECELL<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Use of bromelain based enzymatic debridement in combination with skin cell suspension autograft application for deep facial burns (1102)<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Aaron Hong, MD<br \/>University Medical Center Burn Center, Louisiana State University Health Sciences Center, New Orleans, LA<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">6<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">RECELL<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Skin Cell Suspension (SCSA) for Complex Necrotizing Soft Tissue Infections: A Case Series (1014)<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Beverley Trutter, MD, MPH<br \/>University of Arizona-Department of Surgery, AZ<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">7<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">RECELL GO<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Comparative evaluation of burn patient skin cell solution: Manual versus automated autologous cell preparation (535)<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Sigrid Blome-Eberwein, MD, FABA<br \/>Lehigh Valley Health Network, PA<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">8<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">PermeaDerm + RECELL<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Biosynthetic Wound Matrix with Autologous Skin Cell Suspension Improves Donor Site Healing Time (844)<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Alyssa Brown, MD, PhD<br \/>Texas Tech University Health Sciences Center, TX<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">9<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">RECELL Mini<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Pediatric Burn Care Treatment Using Mini Automated Autologous Cell Harvesting Device: A Tertiary Case Study (1108)<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Katrina Weaver, MD<br \/>Logan Health Children\u2019s, MT<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">10<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Cohealyx<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Bovine Collagen Dermal Matrix Facilitates Re-epithelialization in Mixed Partial-thickness Burn Wounds: A Case Series (1011)<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Hana Gabrielle Lopez-Quinones, MD<br \/>Jacobi Medical Center, NY<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">11<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Cohealyx<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">A Bovine Dermal Collagen Matrix for Deep Partial-Thickness Burns: A Case Series (830)<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Patrick John Kennedy, BS<br \/>The Ohio State Comprehensive Burn Center, OH<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">12<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">PermeaDerm<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Ease of aftercare using a biosynthetic wound matrix for full-thickness wound matrix for full-thickness wound temporization (829)<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Patrick John Kennedy, BS<br \/>The Ohio State Comprehensive Burn Center, OH<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">13<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">PermeaDerm<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">A retrospective review of Biosynthetic Wound Matrix in management of the split-thickness donor site (545)<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Arpana Jain, MBBS, MBA, FACS, FABA<br \/>Diane &amp; Bruce Halle Arizona Burn Center &#8211; Valleywise Health, AZ<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">14<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">RECELL GO<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">The Use of Autologous Skin Cell Adult Facial Burns: Single Institution Series (547)<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Natalie Dewitte, DO, PGY4<br \/>Temple Burn Center, Temple University Hospital, PA<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">15<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">RECELL<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Compassionate Use of Skin Cell Suspension Autografts in Major Burns: A Single-center, US Experience (530)<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Hope Werenski, MD<br \/>Wake Forest University School of Medicine, NC<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">16<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">RECELL<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Optimizing Timing of Autologous Skin Cell Suspension After Enzymatic Debridement of Porcine Burns (515)<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Adam J. Singer, MD<br \/>Stony Brook University, NY<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">17<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">PermeaDerm<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Evaluating If Promise Meets Practice: Use of a Novel Dual-layer Biosynthetic Wound Matrix (841)<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Bo Hyun Kong, BA<br \/>Emory University School of Medicine, GA<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">18<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">RECELL<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Codelivery of Peptide Amphiphile Nanofiber Hydrogel with Autologous Cell Suspension Facilitating Full-thickness Skin Regeneration (C-955)<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Fiona Melania Wood, FRACS<br \/>Burns Service of Western Australia<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">19<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">RECELL<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">New Skin Cell Suspension Autograft Current Procedural Terminology Codes Impact Payments, Charges and Work Credit (C-953)<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Christopher R. LaChapelle, MD, DPT, FACS<br \/>University of Utah Health, UT<\/td>\n<\/tr>\n<\/table>\n<p>*Subject to schedule change<\/p>\n<p>\n        <strong>About AVITA Medical, Inc.<\/strong>\n      <\/p>\n<p>AVITA Medical\u00ae is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is RECELL\u00ae, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient\u2019s own skin to create Spray-On Skin\u2122, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute Cohealyx\u00ae, an AVITA Medical-branded collagen-based dermal matrix, and the exclusive rights to manufacture, market, sell, and distribute PermeaDerm\u00ae, a biosynthetic wound matrix.<\/p>\n<p>In international markets, RECELL is approved to promote skin healing in a wide range of applications, including thermal burn and trauma wounds. RECELL and RECELL GO\u00ae have received the CE mark in Europe; and RECELL is TGA-registered in Australia, and has PMDA approval in Japan.<\/p>\n<p>To learn more, visit\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wWFAeM9_Dm7Vw7J6YM6ofDNOSyLNkWorxtT1Cf_HcV1m4sUYkDfJebCnXvxbmXRcnjQTkZwWtCcUF_DPgRDoXZhtD9gvtD2oyeWwbUJJJQg=\" rel=\"nofollow\" target=\"_blank\">www.avitamedical.com<\/a>.<\/p>\n<p><strong>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS<\/strong><\/p>\n<p>This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements generally may be identified by the use of words such as \u201cpotential,\u201d and similar words or expressions, and the use of future dates. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation: inability to achieve the clinical study results anticipated, or along the timelines anticipated; failure to obtain and\/or maintain regulatory approvals and comply with applicable regulations; market penetration of our products; changes in the legal or regulatory environments; and other business effects, including the effects of industry, as well as other economic or political conditions outside of the Company\u2019s control<em>. <\/em>Any forward-looking statements made herein are made as of the date of this press release, and the Company undertakes no obligation to publicly update or revise any of these statements, except as required by law. For additional information and other important factors that may cause actual results to differ materially from forward-looking statements, please see the \u201cRisk Factors\u201d section of the Company\u2019s latest Annual Report on Form 10-K and other publicly available filings for a discussion of these and other risks and uncertainties.<\/p>\n<p>\n        <strong>Investor &amp; Media Contact:<\/strong><br \/>\n        <br \/>Ben Atkins<br \/>Phone +1-805 341 1571<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mtf7fy5KsmOdIypaXjcdqu1aZaHkYYhZMh-Q3TQQNOJuM2nO5qDNolh_bO7BX5dJSxZXMt0xdoQzposYGDEHBZINGWIcUv1lPgnYnrRD3xGcJY_2mENt3dZDRCuo-kdT\" rel=\"nofollow\" target=\"_blank\"><u>investor@avitamedical.com<\/u><\/a> | <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JVRMdS54sizl44HHC0cdTljj6K19THLaNboPzwB_Y47JR9QO9hYdEwD_HZ9U6n0BsbSpXDPcBk1TyRhTDNAX5I1h1WH3uaDrU7QdsEjUmvI=\" rel=\"nofollow\" target=\"_blank\"><u>media@avitamedical.com<\/u><\/a><\/p>\n<p>Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.<\/p>\n<p>\u00a92026 AVITA Medical. AVITA Medical\u00ae, Cohealyx\u00ae, RECELL\u00ae, RECELL GO\u00ae, and Spray-On Skin<sup>TM<\/sup> Cells are trademarks of AVITA Medical. PermeaDerm\u00ae is a registered trademark owned by Stedical Scientific, Inc. All other trademarks are the properties of their respective owners.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTQ2OSM3NTIzNDQ5IzIxODE1MTA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NWQ3MTEzNjgtNjA3Yi00NzIwLWE4MWUtMDdkNDQxZGUyZWVhLTExOTMwNzktMjAyNi0wNC0wNy1lbg==\/tiny\/AVITA-Medical.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Cohealyx\u00ae multi-center study interim analysis and new case data to be presented RECELL\u00ae and PermeaDerm\u00ae data reinforce a comprehensive approach to wound healing Evidence demonstrates potential to improve outcomes while reducing hospital length of stay and optimizing resource utilization VALENCIA, Calif., April 07, 2026 (GLOBE NEWSWIRE) &#8212; AVITA Medical\u00ae, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced its presence at the 2026 American Burn Association (ABA) Annual Meeting, where new clinical study data on Cohealyx will be presented at a Company-sponsored symposium, alongside investigator-led presentations showcasing real-world clinical experience across the Company\u2019s wound care portfolio. &#8220;The data being presented at ABA reinforces the strong clinical foundation behind RECELL, while introducing new case-based insights on &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-949643","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Cohealyx\u00ae multi-center study interim analysis and new case data to be presented RECELL\u00ae and PermeaDerm\u00ae data reinforce a comprehensive approach to wound healing Evidence demonstrates potential to improve outcomes while reducing hospital length of stay and optimizing resource utilization VALENCIA, Calif., April 07, 2026 (GLOBE NEWSWIRE) &#8212; AVITA Medical\u00ae, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced its presence at the 2026 American Burn Association (ABA) Annual Meeting, where new clinical study data on Cohealyx will be presented at a Company-sponsored symposium, alongside investigator-led presentations showcasing real-world clinical experience across the Company\u2019s wound care portfolio. &#8220;The data being presented at ABA reinforces the strong clinical foundation behind RECELL, while introducing new case-based insights on &hellip; Continue reading &quot;AVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-07T20:40:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTQ2OSM3NTIzNDQ5IzIxODE1MTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data\",\"datePublished\":\"2026-04-07T20:40:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\\\/\"},\"wordCount\":1295,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NTQ2OSM3NTIzNDQ5IzIxODE1MTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\\\/\",\"name\":\"AVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NTQ2OSM3NTIzNDQ5IzIxODE1MTA=\",\"datePublished\":\"2026-04-07T20:40:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NTQ2OSM3NTIzNDQ5IzIxODE1MTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NTQ2OSM3NTIzNDQ5IzIxODE1MTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\/","og_locale":"en_US","og_type":"article","og_title":"AVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data - Market Newsdesk","og_description":"Cohealyx\u00ae multi-center study interim analysis and new case data to be presented RECELL\u00ae and PermeaDerm\u00ae data reinforce a comprehensive approach to wound healing Evidence demonstrates potential to improve outcomes while reducing hospital length of stay and optimizing resource utilization VALENCIA, Calif., April 07, 2026 (GLOBE NEWSWIRE) &#8212; AVITA Medical\u00ae, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced its presence at the 2026 American Burn Association (ABA) Annual Meeting, where new clinical study data on Cohealyx will be presented at a Company-sponsored symposium, alongside investigator-led presentations showcasing real-world clinical experience across the Company\u2019s wound care portfolio. &#8220;The data being presented at ABA reinforces the strong clinical foundation behind RECELL, while introducing new case-based insights on &hellip; Continue reading \"AVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-07T20:40:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTQ2OSM3NTIzNDQ5IzIxODE1MTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data","datePublished":"2026-04-07T20:40:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\/"},"wordCount":1295,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTQ2OSM3NTIzNDQ5IzIxODE1MTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\/","name":"AVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTQ2OSM3NTIzNDQ5IzIxODE1MTA=","datePublished":"2026-04-07T20:40:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTQ2OSM3NTIzNDQ5IzIxODE1MTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTQ2OSM3NTIzNDQ5IzIxODE1MTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949643","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=949643"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949643\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=949643"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=949643"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=949643"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}